ES3076129T3 - Methods of treating prostate cancer - Google Patents
Methods of treating prostate cancerInfo
- Publication number
- ES3076129T3 ES3076129T3 ES22713194T ES22713194T ES3076129T3 ES 3076129 T3 ES3076129 T3 ES 3076129T3 ES 22713194 T ES22713194 T ES 22713194T ES 22713194 T ES22713194 T ES 22713194T ES 3076129 T3 ES3076129 T3 ES 3076129T3
- Authority
- ES
- Spain
- Prior art keywords
- methods
- prostate cancer
- treating prostate
- treating
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160319P | 2021-03-12 | 2021-03-12 | |
| PCT/US2022/019662 WO2022192481A1 (en) | 2021-03-12 | 2022-03-10 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3076129T3 true ES3076129T3 (en) | 2026-08-12 |
Family
ID=80952117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22713194T Active ES3076129T3 (en) | 2021-03-12 | 2022-03-10 | Methods of treating prostate cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12016847B2 (es) |
| EP (1) | EP4304589B1 (es) |
| JP (1) | JP2024510975A (es) |
| KR (1) | KR20230156107A (es) |
| CN (1) | CN117241797A (es) |
| ES (1) | ES3076129T3 (es) |
| WO (1) | WO2022192481A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR073923A1 (es) | 2008-10-31 | 2010-12-09 | Medivation Technologies Inc | Pirido( 4,3-b) indoles que contienen restos rigidos |
| CN102257076B (zh) | 2008-12-18 | 2014-07-30 | 纳幕尔杜邦公司 | 具有新颜料的粉末涂料组合物 |
| US8580399B2 (en) | 2011-04-08 | 2013-11-12 | Universal Display Corporation | Substituted oligoazacarbazoles for light emitting diodes |
| KR20140068883A (ko) | 2011-09-28 | 2014-06-09 | 이데미쓰 고산 가부시키가이샤 | 유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자 |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2961747B1 (en) | 2013-02-27 | 2017-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| US9458156B2 (en) * | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EA201990240A1 (ru) * | 2013-12-24 | 2019-06-28 | Бристол-Маерс Сквибб Компани | Новые трициклические соединения в качестве противораковых средств |
| US9580430B2 (en) * | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| RU2745999C1 (ru) * | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| US20190134004A1 (en) * | 2016-06-16 | 2019-05-09 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| CN111356695B (zh) * | 2017-10-27 | 2022-12-30 | 北京加科思新药研发有限公司 | 新的三环化合物 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
-
2022
- 2022-03-07 US US17/653,717 patent/US12016847B2/en active Active
- 2022-03-10 CN CN202280032513.3A patent/CN117241797A/zh active Pending
- 2022-03-10 KR KR1020237034510A patent/KR20230156107A/ko active Pending
- 2022-03-10 WO PCT/US2022/019662 patent/WO2022192481A1/en not_active Ceased
- 2022-03-10 JP JP2023555527A patent/JP2024510975A/ja active Pending
- 2022-03-10 EP EP22713194.3A patent/EP4304589B1/en active Active
- 2022-03-10 ES ES22713194T patent/ES3076129T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220296574A1 (en) | 2022-09-22 |
| KR20230156107A (ko) | 2023-11-13 |
| JP2024510975A (ja) | 2024-03-12 |
| WO2022192481A1 (en) | 2022-09-15 |
| US12016847B2 (en) | 2024-06-25 |
| EP4304589A1 (en) | 2024-01-17 |
| CN117241797A (zh) | 2023-12-15 |
| EP4304589B1 (en) | 2026-06-17 |
| EP4304589C0 (en) | 2026-06-17 |